AU2013305904B2 - Antibodies to quetiapine haptens and use thereof - Google Patents

Antibodies to quetiapine haptens and use thereof Download PDF

Info

Publication number
AU2013305904B2
AU2013305904B2 AU2013305904A AU2013305904A AU2013305904B2 AU 2013305904 B2 AU2013305904 B2 AU 2013305904B2 AU 2013305904 A AU2013305904 A AU 2013305904A AU 2013305904 A AU2013305904 A AU 2013305904A AU 2013305904 B2 AU2013305904 B2 AU 2013305904B2
Authority
AU
Australia
Prior art keywords
quetiapine
antibody
sample
labeled
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013305904A
Other languages
English (en)
Other versions
AU2013305904A1 (en
Inventor
Linda COLT
Thomas R. DECORY
Matthew Garrett DONAHUE
Yong Gong
Eric Hryhorenko
Bart M. REMMERIE
Rhys Salter
Banumathi Sankaran
Theresa TUBBS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saladax Biomedical Inc
Original Assignee
Saladax Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saladax Biomedical Inc filed Critical Saladax Biomedical Inc
Publication of AU2013305904A1 publication Critical patent/AU2013305904A1/en
Assigned to JANSSEN PHARMACEUTICA NV reassignment JANSSEN PHARMACEUTICA NV Request for Assignment Assignors: JANSSEN PHARMACEUTICA NV, ORTHO-CLINICAL DIAGNOSTICS, INC
Application granted granted Critical
Publication of AU2013305904B2 publication Critical patent/AU2013305904B2/en
Priority to AU2017261579A priority Critical patent/AU2017261579B2/en
Assigned to SALADAX BIOMEDICAL INC. reassignment SALADAX BIOMEDICAL INC. Request for Assignment Assignors: JANSSEN PHARMACEUTICA NV
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9466—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2013305904A 2012-08-21 2013-08-20 Antibodies to quetiapine haptens and use thereof Active AU2013305904B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017261579A AU2017261579B2 (en) 2012-08-21 2017-11-16 Antibodies to quetiapine haptens and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691598P 2012-08-21 2012-08-21
US61/691,598 2012-08-21
PCT/US2013/055830 WO2014031665A1 (en) 2012-08-21 2013-08-20 Antibodies to quetiapine haptens and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017261579A Division AU2017261579B2 (en) 2012-08-21 2017-11-16 Antibodies to quetiapine haptens and use thereof

Publications (2)

Publication Number Publication Date
AU2013305904A1 AU2013305904A1 (en) 2015-03-05
AU2013305904B2 true AU2013305904B2 (en) 2017-08-17

Family

ID=50148312

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013305904A Active AU2013305904B2 (en) 2012-08-21 2013-08-20 Antibodies to quetiapine haptens and use thereof
AU2017261579A Active AU2017261579B2 (en) 2012-08-21 2017-11-16 Antibodies to quetiapine haptens and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017261579A Active AU2017261579B2 (en) 2012-08-21 2017-11-16 Antibodies to quetiapine haptens and use thereof

Country Status (10)

Country Link
US (3) US9850318B2 (cg-RX-API-DMAC7.html)
EP (3) EP3385284B1 (cg-RX-API-DMAC7.html)
JP (2) JP6450314B2 (cg-RX-API-DMAC7.html)
CN (2) CN110054693A (cg-RX-API-DMAC7.html)
AU (2) AU2013305904B2 (cg-RX-API-DMAC7.html)
CA (1) CA2882597C (cg-RX-API-DMAC7.html)
ES (3) ES2935460T3 (cg-RX-API-DMAC7.html)
PL (3) PL2888286T3 (cg-RX-API-DMAC7.html)
PT (3) PT3663317T (cg-RX-API-DMAC7.html)
WO (1) WO2014031665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2933478T3 (es) * 2005-08-03 2023-02-09 Astellas Inst For Regenerative Medicine Métodos mejorados de reprogramación de células somáticas animales
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
JP6450314B2 (ja) * 2012-08-21 2019-01-09 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンハプテンに対する抗体及びその使用
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
CN107043424B (zh) 2012-08-21 2021-03-16 詹森药业有限公司 利培酮的抗体及其用途
ES2822004T3 (es) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticuerpos contra quetiapina y uso de los mismos
AU2013305901B2 (en) 2012-08-21 2017-10-26 Saladax Biomedical Inc. Antibodies to olanzapine and use thereof
CN104736561B (zh) 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
JP6389176B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールハプテンに対する抗体及びその使用
CN108517014A (zh) 2012-08-21 2018-09-11 詹森药业有限公司 利培酮半抗原的抗体及其用途
WO2017106508A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
CN110938082A (zh) * 2019-10-30 2020-03-31 杭州博拓生物科技股份有限公司 一种奥氮平人工抗原及其制备方法
CN111808046B (zh) * 2020-06-30 2022-11-11 杭州同舟生物技术有限公司 一种喹硫平人工半抗原、人工抗原及其制备方法和应用
CN115073492B (zh) * 2022-08-22 2022-11-18 北京丹大生物技术有限公司 一种奥氮平衍生物抗原、奥氮平抗体及其应用
CN116354904B (zh) * 2023-04-26 2023-08-01 北京丹大生物技术有限公司 一种喹硫平衍生物半抗原、抗原、抗喹硫平抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011082076A1 (en) * 2009-12-31 2011-07-07 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
WO2011112657A1 (en) * 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
WO2011115733A1 (en) * 2010-03-16 2011-09-22 Saladax Biomedical Inc. Risperidone immunoassay

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ES2184734T3 (es) 1987-04-27 2003-04-16 Inverness Medical Switzerland Dispositivo de prueba analitica para realizar ensayos de union especifica.
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
NO305125B1 (no) 1992-05-29 1999-04-06 Lilly Industries Ltd Farmas°ytiske forbindelser
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
EP0804580B1 (en) 1994-06-10 2008-10-08 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US6139800A (en) 1997-06-23 2000-10-31 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
ES2358737T3 (es) * 2002-01-31 2011-05-13 Randox Laboratories Ltd. Inmunógenos, anticuerpos y conjugados para cetamina y sus metabolitos.
DE60334364D1 (de) 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
PT1488040E (pt) 2002-03-04 2012-06-01 Amcol International Corp Papel e materiais e processos para a sua produção
ES2297142T3 (es) 2002-03-28 2008-05-01 Eli Lilly And Company Arilbenzodiazepinas sustituidas con piperazina y su uso como antagonistas del receptor de dopamina para el tratamiento de trastornos psicoticos.
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
WO2004011031A1 (en) 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
AU2003264915A1 (en) 2002-08-05 2004-02-25 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
EP1626993B1 (en) 2003-05-09 2015-03-11 Duke University Cd20-specific antibodies and methods of employing same
BRPI0413595B8 (pt) * 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
PT1664007E (pt) 2003-09-23 2010-02-15 Fermion Oy Preparação de quetiapina
CN101921279A (zh) 2003-10-01 2010-12-22 阿得罗公司 螺环杂环衍生物及其应用方法
EP1675573B2 (en) 2003-10-23 2012-06-13 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
AU2004298660B2 (en) * 2003-12-12 2010-04-22 Abbott Rapid Diagnostics International Unlimited Company Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
EP1748070A4 (en) 2004-04-26 2007-07-18 Takami Matsuyama THERAPEUTIC WITH MONOCLONAL ANTIBODY AGAINST FOLAT RECEPTOR BETA (FR-BETA)
US7087699B2 (en) 2004-05-17 2006-08-08 Acushnet Company Sulfur-containing composition for golf equipment, and method of using same
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
FR2878850B1 (fr) 2004-12-02 2008-10-31 Cis Bio Internat Sa Derives de l'inositol-1-phosphate
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE0501418L (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
EP2077860B1 (en) * 2006-10-25 2014-04-09 Ramot at Tel-Aviv University Ltd Psychotropic agents having glutamate nmda activity
CA3069091C (en) * 2006-11-01 2021-09-14 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
WO2008082979A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
CN100482643C (zh) * 2007-01-19 2009-04-29 中国科学院广州生物医药与健康研究院 一种氨基脲衍生物及其单克隆抗体与应用
CN101091700B (zh) * 2007-07-03 2011-06-08 上海现代药物制剂工程研究中心有限公司 富马酸喹硫平缓控释制剂组合物及其制备用途
KR20100075455A (ko) 2007-09-27 2010-07-02 노파르티스 아게 약물 모니터링 분석법
KR101706789B1 (ko) * 2008-07-21 2017-02-14 프로비오드룩 아게 진단용 항체 검사법
JP2011529923A (ja) 2008-08-06 2011-12-15 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
WO2010043893A1 (en) 2008-10-14 2010-04-22 Astrazeneca Ab Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
EP2347015A4 (en) 2008-10-29 2012-12-19 Janssen Pharmaceutica Nv METHOD FOR THE TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GEN
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US8480333B2 (en) 2008-12-26 2013-07-09 Steven Edward DeMay Frame rail assemblies and interlocking frame rail systems
WO2010083843A1 (en) * 2009-01-26 2010-07-29 Egalet A/S Controlled release formulations with continuous efficacy
JP5883653B2 (ja) 2009-03-10 2016-03-15 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング抗ウイルスワクチン
WO2011159537A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US8913245B2 (en) 2010-06-29 2014-12-16 Kla-Tencor Corporation System and method for interferometric autofocusing
WO2012003418A2 (en) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
CN102190724A (zh) * 2011-03-31 2011-09-21 上海大学 十氯酮抗原、抗体及其制备方法
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
PE20151138A1 (es) 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n
EP3415516B1 (en) 2012-08-21 2021-12-15 Janssen Pharmaceutica NV Haptens of risperidone and paliperidone
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
CN108517014A (zh) 2012-08-21 2018-09-11 詹森药业有限公司 利培酮半抗原的抗体及其用途
ES2822004T3 (es) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticuerpos contra quetiapina y uso de los mismos
JP6389176B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールハプテンに対する抗体及びその使用
CN107043424B (zh) 2012-08-21 2021-03-16 詹森药业有限公司 利培酮的抗体及其用途
ES2739383T3 (es) 2012-08-21 2020-01-30 Janssen Pharmaceutica Nv Haptenos de paliperidona
CN104736561B (zh) 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
PT3305784T (pt) 2012-08-21 2020-10-23 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
JP6450314B2 (ja) * 2012-08-21 2019-01-09 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンハプテンに対する抗体及びその使用
AU2013305901B2 (en) 2012-08-21 2017-10-26 Saladax Biomedical Inc. Antibodies to olanzapine and use thereof
CA2882454C (en) 2012-08-21 2020-08-11 Matthew Garrett DONAHUE Haptens of olanzapine
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017106508A1 (en) * 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011082076A1 (en) * 2009-12-31 2011-07-07 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
WO2011112657A1 (en) * 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
WO2011115733A1 (en) * 2010-03-16 2011-09-22 Saladax Biomedical Inc. Risperidone immunoassay

Also Published As

Publication number Publication date
EP3385284A1 (en) 2018-10-10
CN110054693A (zh) 2019-07-26
PT2888286T (pt) 2018-05-09
US10465013B2 (en) 2019-11-05
EP3385284B1 (en) 2020-02-26
JP6637580B2 (ja) 2020-01-29
ES2664952T3 (es) 2018-04-24
EP2888286B1 (en) 2018-02-21
EP2888286A1 (en) 2015-07-01
PL3385284T3 (pl) 2020-09-21
PL3663317T3 (pl) 2023-06-05
JP6450314B2 (ja) 2019-01-09
EP2888286A4 (en) 2016-03-23
HK1211959A1 (en) 2016-06-03
ES2935460T3 (es) 2023-03-07
WO2014031665A1 (en) 2014-02-27
AU2017261579A1 (en) 2017-12-07
AU2013305904A1 (en) 2015-03-05
CA2882597C (en) 2020-04-14
CN104736564B (zh) 2019-02-05
US20200040107A1 (en) 2020-02-06
US20140057305A1 (en) 2014-02-27
CA2882597A1 (en) 2014-02-27
US20210017294A9 (en) 2021-01-21
PT3385284T (pt) 2020-05-20
US20180105606A1 (en) 2018-04-19
JP2015529203A (ja) 2015-10-05
PL2888286T3 (pl) 2018-07-31
ES2788716T3 (es) 2020-10-22
PT3663317T (pt) 2023-01-23
US9850318B2 (en) 2017-12-26
AU2017261579B2 (en) 2019-11-07
EP3663317B1 (en) 2022-10-12
CN104736564A (zh) 2015-06-24
JP2019073513A (ja) 2019-05-16
EP3663317A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
AU2013305904B2 (en) Antibodies to quetiapine haptens and use thereof
AU2018200435B2 (en) Antibodies to olanzapine haptens and use thereof
AU2013305970B2 (en) Antibodies to aripiprazole haptens and use thereof
AU2013305938B2 (en) Antibodies to paliperidone haptens and use thereof
AU2017264980A1 (en) Haptens of quetiapine for use in immunoassays
HK1253809A1 (en) Haptens of quetiapine for use in immunoassays
HK40030125A (en) Antibodies to quetiapine haptens and use thereof
HK1261382B (en) Antibodies to quetiapine haptens and use thereof
HK1261382A1 (en) Antibodies to quetiapine haptens and use thereof
HK40030125B (en) Antibodies to quetiapine haptens and use thereof
HK1211959B (en) Antibodies to quetiapine haptens and use thereof
HK1211955B (en) Antibodies to aripiprazole haptens and use thereof
HK1211931B (en) Haptens of quetiapine for use in immunoassays

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JANSSEN PHARMACEUTICA NV

Free format text: FORMER APPLICANT(S): ORTHO-CLINICAL DIAGNOSTICS, INC; JANSSEN PHARMACEUTICA NV

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SALADAX BIOMEDICAL INC.

Free format text: FORMER OWNER(S): JANSSEN PHARMACEUTICA NV